|
|
||||||||
Administration of IGF-I over a 14-day period to growing female rats via s.c. implanted osmotic pumps led to an increased body weight gain, an improved N retention and a greater food conversion efficiency. The effects were dose-dependent, with the highest daily dose tested, 278 µg/day, producing 18–26% increases in these measurements. LR3IGF-I, a variant of human IGF-I that contains an amino terminal extension peptide as well as glutamate-3 replaced by arginine and exhibits very weak binding to IGF-binding proteins, was substantially more potent than the natural growth factor, in that 44 µg/day of this peptide produced similar effects to the high IGF-I dose. Organ weight and carcass composition measurements showed that the two IGF peptides generally maintained body proportions at those existing when the experiment began. Muscle protein synthesis and myofibrillar protein breakdown were both slightly increased by IGF treatment, so that the observed improvement in N retention could not be explained through protein accretion rates calculated from these measures. Infusion of human GH at a dose of 213 µg/day did not stimulate body growth. This investigation establishes that IGF peptides stimulate the growth of normal growing animals, with IGF-I variants that bind less well to IGF-binding proteins being more active than IGF-I.
Journal of Endocrinology (1993) 137, 413–421
This article has been cited by other articles:
![]() |
D. L Hadsell, A. F Parlow, D. Torres, J. George, and W. Olea Enhancement of maternal lactation performance during prolonged lactation in the mouse by mouse GH and long-R3-IGF-I is linked to changes in mammary signaling and gene expression J. Endocrinol., July 1, 2008; 198(1): 61 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Robertson, Y. Lu, K. De Jesus, B. Li, Q. Su, P. K. Lund, and J.-L. Liu A general and islet cell-enriched overexpression of IGF-I results in normal islet cell growth, hypoglycemia, and significant resistance to experimental diabetes Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E928 - E938. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. G. Hollier, J. A. Kricker, D. R. Van Lonkhuyzen, D. I. Leavesley, and Z. Upton Substrate-Bound Insulin-Like Growth Factor (IGF)-I-IGF Binding Protein-Vitronectin-Stimulated Breast Cell Migration Is Enhanced by Coactivation of the Phosphatidylinositide 3-Kinase/AKT Pathway by {alpha}v-Integrins and the IGF-I Receptor Endocrinology, March 1, 2008; 149(3): 1075 - 1090. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Z. Michaylira, J. G. Simmons, N. M. Ramocki, B. P. Scull, K. K. McNaughton, C. R. Fuller, and P. K. Lund Suppressor of cytokine signaling-2 limits intestinal growth and enterotrophic actions of IGF-I in vivo Am J Physiol Gastrointest Liver Physiol, September 1, 2006; 291(3): G472 - G481. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Haddad and G. R. Adams Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy J Appl Physiol, April 1, 2006; 100(4): 1188 - 1203. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Hadsell, D. T. Torres, N. A. Lawrence, J. George, A. F. Parlow, A. V. Lee, and M. L. Fiorotto Overexpression of Des(1-3) Insulin-Like Growth Factor 1 in the Mammary Glands of Transgenic Mice Delays the Loss of Milk Production with Prolonged Lactation Biol Reprod, December 1, 2005; 73(6): 1116 - 1125. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Vickers, B. A. Ikenasio, and B. H. Breier IGF-I Treatment Reduces Hyperphagia, Obesity, and Hypertension in Metabolic Disorders Induced by Fetal Programming Endocrinology, September 1, 2001; 142(9): 3964 - 3973. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Pell, R. A. Hill, C. E. H. Stewart, C. R. Weston, and H. C. Flick-Smith Enhancement of Insulin-Like Growth Factor I Activity by Novel Antisera: Potential Structure/Function Interactions Endocrinology, February 1, 2000; 141(2): 741 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Robertson, D. A. Belford, and F. J. Ballard Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions Am J Physiol Endocrinol Metab, April 1, 1999; 276(4): E663 - E671. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. R. Adams and S. A. McCue Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats J Appl Physiol, May 1, 1998; 84(5): 1716 - 1722. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Hill and J. M. Pell Regulation of Insulin-Like Growth Factor I (IGF-I) Bioactivity in Vivo: Further Characterization of an IGF-I-Enhancing Antibody Endocrinology, March 1, 1998; 139(3): 1278 - 1287. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Lewis, T. J. Lorusso, and M. Fournier Anabolic influences of insulin-like growth factor I and/or growth hormone on the diaphragm of young rats J Appl Physiol, June 1, 1997; 82(6): 1972 - 1978. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |